BACKGROUND: We hypothesized that only a minority of patients with mood disorders have measurable cognitive impairment, and this minority drives the small-to-medium effect sizes detected in group studies. Removal of this minority from group statistical analyses will illustrate that the majority appear to have broadly normal cognitive functioning. METHODS: Participants were adults between the ages of 20 and 54, including 659 healthy control subjects, 84 unmedicated outpatients diagnosed with depression, 59 outpatients diagnosed with depression who were on medications at the time of the evaluation, and 43 outpatients with bipolar disorder. All completed the CNS Vital Signs computerized cognitive screening battery. RESULTS: The prevalence rates of low cognitive test scores were calculated for the healthy control subjects and the patients with mood disorders. Having two scores at or below the 5th percentile occurred in 31.2% of the patients and only 8.2% of the control subjects [χ(2)(1)=66.67, p<.0001; Odds Ratio=5.1, 95% CI=3.4-7.7]. For the control subjects, this low false positive rate for cognitive impairment was maintained across age groups, sexes, and education levels. A larger proportion of patients with bipolar disorder (41.9%) than patients with depression (27.1-28.6%) met this criterion for cognitive impairment. CONCLUSIONS: This study suggests that cognitive impairment associated with mood disorders is limited to a minority of patients with the majority being broadly cognitively normal. Future research should determine if this identified subgroup has neuroanatomical, neurophysiological, or neuroendocrine abnormalities. Cognitive screening tools of this type might be useful in selecting participants for studies.
BACKGROUND: We hypothesized that only a minority of patients with mood disorders have measurable cognitive impairment, and this minority drives the small-to-medium effect sizes detected in group studies. Removal of this minority from group statistical analyses will illustrate that the majority appear to have broadly normal cognitive functioning. METHODS:Participants were adults between the ages of 20 and 54, including 659 healthy control subjects, 84 unmedicated outpatients diagnosed with depression, 59 outpatients diagnosed with depression who were on medications at the time of the evaluation, and 43 outpatients with bipolar disorder. All completed the CNS Vital Signs computerized cognitive screening battery. RESULTS: The prevalence rates of low cognitive test scores were calculated for the healthy control subjects and the patients with mood disorders. Having two scores at or below the 5th percentile occurred in 31.2% of the patients and only 8.2% of the control subjects [χ(2)(1)=66.67, p<.0001; Odds Ratio=5.1, 95% CI=3.4-7.7]. For the control subjects, this low false positive rate for cognitive impairment was maintained across age groups, sexes, and education levels. A larger proportion of patients with bipolar disorder (41.9%) than patients with depression (27.1-28.6%) met this criterion for cognitive impairment. CONCLUSIONS: This study suggests that cognitive impairment associated with mood disorders is limited to a minority of patients with the majority being broadly cognitively normal. Future research should determine if this identified subgroup has neuroanatomical, neurophysiological, or neuroendocrine abnormalities. Cognitive screening tools of this type might be useful in selecting participants for studies.
Authors: Lucy J Robinson; Jill M Thompson; Peter Gallagher; Utpal Goswami; Allan H Young; I Nicol Ferrier; P Brian Moore Journal: J Affect Disord Date: 2006-03-06 Impact factor: 4.839
Authors: David J Schretlen; Nicola G Cascella; Stephen M Meyer; Lisle R Kingery; S Marc Testa; Cynthia A Munro; Ann E Pulver; Paul Rivkin; Vani A Rao; Catherine M Diaz-Asper; Faith B Dickerson; Robert H Yolken; Godfrey D Pearlson Journal: Biol Psychiatry Date: 2006-12-11 Impact factor: 13.382
Authors: Russell M Bauer; Grant L Iverson; Alison N Cernich; Laurence M Binder; Ronald M Ruff; Richard I Naugle Journal: Arch Clin Neuropsychol Date: 2012-03-01 Impact factor: 2.813
Authors: Russell M Bauer; Grant L Iverson; Alison N Cernich; Laurence M Binder; Ronald M Ruff; Richard I Naugle Journal: Clin Neuropsychol Date: 2012-03-07 Impact factor: 3.535
Authors: K K Meyers; N A Crane; R O'Day; J K Zubieta; B Giordani; C S Pomerleau; J C Horowitz; S A Langenecker Journal: Addict Behav Date: 2014-10-23 Impact factor: 3.913
Authors: Natania A Crane; Lisanne M Jenkins; Runa Bhaumik; Catherine Dion; Jennifer R Gowins; Brian J Mickey; Jon-Kar Zubieta; Scott A Langenecker Journal: Brain Date: 2017-01-24 Impact factor: 13.501
Authors: J Volkert; M A Schiele; Julia Kazmaier; Friederike Glaser; K C Zierhut; J Kopf; S Kittel-Schneider; A Reif Journal: Eur Arch Psychiatry Clin Neurosci Date: 2015-11-26 Impact factor: 5.270
Authors: Franklin C Brown; Michael Westerveld; John T Langfitt; Marla Hamberger; Hamada Hamid; Shlomo Shinnar; Michael R Sperling; Orrin Devinsky; William Barr; Joseph Tracy; David Masur; Carl W Bazil; Susan S Spencer Journal: Epilepsy Behav Date: 2013-11-26 Impact factor: 2.937
Authors: Raeanne C Moore; Alexandrea L Harmell; Jennifer Ho; Thomas L Patterson; Lisa T Eyler; Dilip V Jeste; Brent T Mausbach Journal: Schizophr Res Date: 2013-01-30 Impact factor: 4.939
Authors: Manisha Madhoo; Richard S E Keefe; Robert M Roth; Angelo Sambunaris; James Wu; Madhukar H Trivedi; Colleen S Anderson; Robert Lasser Journal: Neuropsychopharmacology Date: 2013-12-06 Impact factor: 7.853